Chinese Biotech Bio-Thera Solutions Initiates Ph III Trial of HER2 ADC in Metastatic Breast Cancer

Chinese Biotech Bio-Thera Solutions Initiates Ph III Trial of HER2 ADC in Metastatic Breast Cancer

Source: 
CP Wire
snippet: 
  • BAT8001 is also being studied gastric cancers
  • Bio-Thera recently announced that is BLA for a Humira biosimilar had been accepted for review in China
  • The company is also developing a biosimilar to Actemra